Study Objective: The aim of this study was to evaluate the analgesic efficacy and safety of pectoralisserratus interfascial plane block in comparison with thoracic paravertebral block for postmastectomy pain. Design: A prospective randomized controlled study. Setting: Tertiary center, university hospital. Patients: Sixty-four adult women, American Society of Anesthesiologists physical status classes I, II, and III, scheduled for unilateral modified radical mastectomy with axillary evacuation. Interventions: Patients were randomized to receive either pectoralis-serratus interfascial plane block, PS group (n = 32), or thoracic paravertebral block, PV group (n = 32). Measurements: Twenty-four-hour morphine consumption and the time to rescue analgesic were recorded. The pain intensity evaluated by visual analog scale (VAS) score at 0, 2, 4, 8, 16, and 24 hours postoperatively was also recorded. Main Results: The median (interquartile range) postoperative 24-hour morphine consumption was significantly increased in PS group in comparison to PV group (PS vs PV), 20 mg (16-23 mg) vs 12 mg (10-14 mg) (P b .001). The median postoperative time to first analgesic request was significantly shorter in PS group compared to PV group (PS, 6 hours [5-7 hours], vs PV, 11 hours [9-13 hours]) (P b .001). The intensity of pain was low in both groups inVAS 0, 2, and 4 hours postoperatively. However, therewas significant reduction in VAS in PV group compared to PS group at 8, 16, and 24 hours postoperatively. Conclusions: Pectoralis-serratus interfascial plane block was safe and easy to perform and decreased intensity of postmastectomy pain, but it was inferior to thoracic paravertebral block. © 2016 Elsevier Inc. All rights reserved.

Study Objective: The aim of this study was to evaluate the analgesic efficacy and safety of pectoralisserratus interfascial plane block in comparison with thoracic paravertebral block for postmastectomy pain. Design: A prospective randomized controlled study. Setting: Tertiary center, university hospital. Patients: Sixty-four adult women, American Society of Anesthesiologists physical status classes I, II, and III, scheduled for unilateral modified radical mastectomy with axillary evacuation. Interventions: Patients were randomized to receive either pectoralis-serratus interfascial plane block, PS group (n = 32), or thoracic paravertebral block, PV group (n = 32). Measurements: Twenty-four-hour morphine consumption and the time to rescue analgesic were recorded. The pain intensity evaluated by visual analog scale (VAS) score at 0, 2, 4, 8, 16, and 24 hours postoperatively was also recorded. Main Results: The median (interquartile range) postoperative 24-hour morphine consumption was significantly increased in PS group in comparison to PV group (PS vs PV), 20 mg (16-23 mg) vs 12 mg (10-14 mg) (P b .001). The median postoperative time to first analgesic request was significantly shorter in PS group compared to PV group (PS, 6 hours [5-7 hours], vs PV, 11 hours [9-13 hours]) (P b .001). The intensity of pain was low in both groups inVAS 0, 2, and 4 hours postoperatively. However, therewas significant reduction in VAS in PV group compared to PS group at 8, 16, and 24 hours postoperatively. Conclusions: Pectoralis-serratus interfascial plane block was safe and easy to perform and decreased intensity of postmastectomy pain, but it was inferior to thoracic paravertebral block. © 2016 Elsevier Inc. All rights reserved.

Study objective:We hypothesized that oral administration of a single dose of pregabalin 2 hours before modified radical mastectomy (MRM) would produce dose-related reduction in postoperative opioid consumption. Design: Prospective randomized controlled clinical trial. Setting: Postanesthesia care unit. Patients: One hundred twenty adult women scheduled for unilateral (MRM) with axillary evacuation. Interventions: Patients were randomized to receive either, placebo capsule, pregabalin 75 mg, pregabalin 150 mg, or pregabalin 300 mg. Measurements: The assessment parameters were the postoperative analgesic effect using visual analog scale (VAS) pain scores, the subsequent 24-hour morphine consumption, and the systemic adverse effects of pregabalin doses. Main results: The VAS score at rest and movement was significantly decreased only in group P300 and group P150 in comparison to group P0 and group P75 at 0 hour (P b .01). The median (interquartile range) consumption of morphine in the first postoperative 24 hours was significantly decreased in group P300 in comparison to group P0 and group P75 (P300 vs P0: 6.5 [5-6.5] vs 20.5 [15.8-20.5] [P b .001]; P300 vs P75: 6.5 [5-6.5] vs 20 [14-20] [P b .001]), but there was no significant difference between group P300 and group P150. In addition, there was a significant decrease in consumption of morphine in group P150 in comparison to group P0 and group P75 (P150 vs P0: 7 [5-7] vs 20.5 [15.8-20.5] [P b .001]; P150 vs P75: 7 [5-7] vs 20 [14-20] [P b .001]). There were statistical significant increase in dizziness and blurred vision in group P300 in comparison to other groups (P b .05). Conclusions: A single preoperative oral dose of pregabalin 150 mg is an optimal dose for reducing postoperative pain and morphine consumption in patients undergoing MRM. © 2016 Elsevier Inc. All rights reserved.

Study objective:We hypothesized that oral administration of a single dose of pregabalin 2 hours before modified radical mastectomy (MRM) would produce dose-related reduction in postoperative opioid consumption. Design: Prospective randomized controlled clinical trial. Setting: Postanesthesia care unit. Patients: One hundred twenty adult women scheduled for unilateral (MRM) with axillary evacuation. Interventions: Patients were randomized to receive either, placebo capsule, pregabalin 75 mg, pregabalin 150 mg, or pregabalin 300 mg. Measurements: The assessment parameters were the postoperative analgesic effect using visual analog scale (VAS) pain scores, the subsequent 24-hour morphine consumption, and the systemic adverse effects of pregabalin doses. Main results: The VAS score at rest and movement was significantly decreased only in group P300 and group P150 in comparison to group P0 and group P75 at 0 hour (P b .01). The median (interquartile range) consumption of morphine in the first postoperative 24 hours was significantly decreased in group P300 in comparison to group P0 and group P75 (P300 vs P0: 6.5 [5-6.5] vs 20.5 [15.8-20.5] [P b .001]; P300 vs P75: 6.5 [5-6.5] vs 20 [14-20] [P b .001]), but there was no significant difference between group P300 and group P150. In addition, there was a significant decrease in consumption of morphine in group P150 in comparison to group P0 and group P75 (P150 vs P0: 7 [5-7] vs 20.5 [15.8-20.5] [P b .001]; P150 vs P75: 7 [5-7] vs 20 [14-20] [P b .001]). There were statistical significant increase in dizziness and blurred vision in group P300 in comparison to other groups (P b .05). Conclusions: A single preoperative oral dose of pregabalin 150 mg is an optimal dose for reducing postoperative pain and morphine consumption in patients undergoing MRM. © 2016 Elsevier Inc. All rights reserved.

Study objective:We hypothesized that oral administration of a single dose of pregabalin 2 hours before modified radical mastectomy (MRM) would produce dose-related reduction in postoperative opioid consumption. Design: Prospective randomized controlled clinical trial. Setting: Postanesthesia care unit. Patients: One hundred twenty adult women scheduled for unilateral (MRM) with axillary evacuation. Interventions: Patients were randomized to receive either, placebo capsule, pregabalin 75 mg, pregabalin 150 mg, or pregabalin 300 mg. Measurements: The assessment parameters were the postoperative analgesic effect using visual analog scale (VAS) pain scores, the subsequent 24-hour morphine consumption, and the systemic adverse effects of pregabalin doses. Main results: The VAS score at rest and movement was significantly decreased only in group P300 and group P150 in comparison to group P0 and group P75 at 0 hour (P b .01). The median (interquartile range) consumption of morphine in the first postoperative 24 hours was significantly decreased in group P300 in comparison to group P0 and group P75 (P300 vs P0: 6.5 [5-6.5] vs 20.5 [15.8-20.5] [P b .001]; P300 vs P75: 6.5 [5-6.5] vs 20 [14-20] [P b .001]), but there was no significant difference between group P300 and group P150. In addition, there was a significant decrease in consumption of morphine in group P150 in comparison to group P0 and group P75 (P150 vs P0: 7 [5-7] vs 20.5 [15.8-20.5] [P b .001]; P150 vs P75: 7 [5-7] vs 20 [14-20] [P b .001]). There were statistical significant increase in dizziness and blurred vision in group P300 in comparison to other groups (P b .05). Conclusions: A single preoperative oral dose of pregabalin 150 mg is an optimal dose for reducing postoperative pain and morphine consumption in patients undergoing MRM. © 2016 Elsevier Inc. All rights reserved.

NULL

NULL

NULL

NULL

NULL